Autosomal dominant polycystic kidney disease, or ADPKD, affects roughly 1 in every 1,000 to 2,500 people worldwide, making it one of the most common inherited kidney disorders. But that range hides a significant complication: the number of people who have been diagnosed with ADPKD is substantially lower than the number who actually carry the genetic mutations responsible for it. Large studies in the United States and Europe consistently find that diagnosed prevalence sits well below what genetic screening would predict, which means a meaningful fraction of people with ADPKD don’t yet know they have it.
How Common Is ADPKD Across Populations
The figures you encounter depend heavily on where the data come from and how the cases were identified. A large European study combining a German registry with British general-practice data found a minimum diagnosed prevalence of about 2.4 to 3.9 per 10,000 people. After adjusting for cases that would be found through family screening, the estimated prevalence rose to around 3.3 to 4.6 per 10,000, though still under 5 per 10,000 in both populations studied.1Nephrology Dialysis Transplantation. Prevalence of autosomal dominant polycystic kidney disease in the European Union In a US population of several million people tracked from 2002 to 2018, the diagnosed prevalence was about 43 per 100,000, or roughly 4.3 per 10,000.2PubMed Central. Autosomal Dominant Polycystic Kidney Disease Prevalence among a Racially Diverse United States Population, 2002 through 2018
In Colombia, the picture looks a bit different. Reported prevalence rates varied widely by region, with the highest adjusted rate at about 6.6 per 100,000 in one department and reaching roughly 9.4 per 100,000 in the city of Cali.3PubMed Central. Autosomal dominant polycystic kidney disease in Colombia These numbers are lower than the European and North American figures, which almost certainly reflects differences in access to diagnostic imaging and kidney-disease awareness rather than a genuinely lower burden of disease.
Within the United States, prevalence also varies by region. A study examining census regions found two-year prevalence was highest in the Northeast at about 4.1 per 10,000 and lowest in the West at roughly 3.4 per 10,000, with a significant correlation between prevalence and the proportion of people living in urban areas.4PubMed. Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States More doctors, more ultrasound machines, and more routine check-ups translate into more diagnoses. That pattern shows up almost everywhere: wherever healthcare access is denser, the number of identified ADPKD cases climbs.
Why So Many Cases Go Undiagnosed
ADPKD is unusual among genetic diseases because it develops slowly and quietly. Most people with the condition are born with kidneys that look normal on imaging. Cysts grow gradually over decades, and many individuals feel perfectly fine until their kidney function has already declined significantly. The disease can remain invisible on a standard physical exam for years, and unless someone gets an abdominal ultrasound or cross-sectional scan for an unrelated reason, the cysts simply go unnoticed.
This matters for prevalence numbers because most estimates rely on clinical diagnoses, meaning someone had to show up in a medical record with an ADPKD code. People who carry the mutation but haven’t been scanned, or whose cysts are still too small to detect on ultrasound, are invisible to these studies. Genetic studies, where researchers sequence DNA in large populations without requiring a prior clinical diagnosis, consistently suggest the true prevalence is higher than what any claims-database study can capture.
Another factor pushing down the diagnosed count is the existence of de novo mutations. Not everyone with ADPKD inherits it from a parent. Research has confirmed cases where a person’s ADPKD-causing mutation appeared for the first time, with neither biological parent carrying the variant.5PubMed Central. Presence of De Novo Mutations in Autosomal Dominant Polycystic Kidney Disease Patients Without Family History People without a family history of the disease are less likely to be screened, so these de novo cases often slip through the diagnostic net until they develop obvious symptoms later in life.
Racial and Ethnic Variation in Diagnosis
ADPKD has long been characterized as a disease that affects all ethnic groups equally, since the mutations occur across populations. But diagnosis rates tell a more complicated story. In the large US study spanning 2002 to 2018, diagnosed prevalence per 100,000 was highest among Black patients at 73.0 and non-Hispanic White patients at 63.2, while Hispanic patients had a rate of 39.9 and Asian patients 48.9.2PubMed Central. Autosomal Dominant Polycystic Kidney Disease Prevalence among a Racially Diverse United States Population, 2002 through 2018
The higher diagnosed prevalence among Black patients was a somewhat surprising finding. One possible explanation is that ADPKD may progress more quickly or become clinically apparent earlier in Black individuals, perhaps because of higher rates of hypertension or other factors that accelerate kidney disease. Another possibility is that the mutations in these populations happen to be more severe on average, though this hasn’t been established. What researchers emphasized is that race likely plays a role in how and when ADPKD shows itself clinically, rather than simply how common the underlying mutation is. Sorting out how much of the difference is biological versus how much reflects healthcare-access patterns remains an active area of research.
PKD1 Versus PKD2 and Why It Matters
Most cases of ADPKD are caused by mutations in one of two genes, PKD1 or PKD2, and the gene involved makes a large difference in how the disease plays out. PKD1 mutations are more common and cause more aggressive disease. In families with PKD1 mutations, the median age at which kidney failure develops is in the mid-50s. For PKD2, that milestone typically doesn’t arrive until about 20 years later, around the early-to-mid 70s.6The Lancet. Comparison of phenotypes of polycystic kidney disease types 1 and 27PubMed Central. Family history of renal disease severity predicts the mutated gene in ADPKD A Spanish cohort study found median renal survival of about 57.5 years for PKD1 and 70 years for PKD2, broadly consistent with those earlier findings.8NefrologÃa (English Edition). The natural history of autosomal dominant polycystic kidney disease. A strategy for grouping families and mutations
This distinction has a quiet but real effect on prevalence estimates. People with PKD2 mutations may live well into their 70s or 80s with adequate kidney function and never receive a formal diagnosis, especially if they aren’t screened. Their cysts grow more slowly, and ultrasound is less reliable at detecting PKD2 in younger patients. A systematic review of ultrasound accuracy found that sensitivity was as low as 31% in PKD2 populations aged 5 to 14, compared to much higher sensitivity in PKD1 groups and in older patients generally.9Clinical Kidney Journal. The diagnostic accuracy of ultrasound and genomic tests for the diagnosis of autosomal-dominant polycystic kidney disease: a systematic mapping review So the milder subtype is also the one most likely to be missed, which means prevalence statistics are disproportionately weighted toward the more severe form of the disease.
ADPKD in Children and Young Adults
Although ADPKD is often thought of as an adult disease, it can be detected much earlier. It has been identified in fetuses, infants, and children, though the vast majority of children found to have it are asymptomatic.10PubMed Central. The spectrum of polycystic kidney disease in children When symptoms do occur in childhood, hypertension and blood in the urine are the most common. A longitudinal study of 154 children from ADPKD families found that by combining clinical history, physical examination, and ultrasonography, ADPKD could be identified in as many as two-thirds of affected children.11Kidney International. Autosomal dominant polycystic kidney disease in childhood: A longitudinal study
The question of whether to screen children from ADPKD families is genuinely contentious. On one hand, early identification allows for blood-pressure monitoring and genetic counseling. On the other, diagnosing a child with a lifelong condition when they are feeling perfectly well creates psychological and insurance-related complications that some families would rather avoid. There is no consensus in the field, and different nephrology groups handle it differently. What is clear is that the disease is already underway in childhood even when it isn’t causing symptoms, and the choice to screen or not is a family decision with real tradeoffs.
What ADPKD Does Beyond the Kidneys
ADPKD isn’t strictly a kidney disease. The proteins encoded by PKD1 and PKD2 are expressed throughout the body, and cysts and other abnormalities can develop in several organs. The liver is the most commonly affected site outside the kidneys. A study of ADPKD patients found hepatic cysts in about 82% of adults, with prevalence increasing with age.12PubMed Central. Liver manifestations in autosomal dominant polycystic kidney disease (ADPKD) and their impact on quality of life Most liver cysts don’t cause serious medical problems, but in some patients, particularly women, they can grow large enough to cause pain, early satiety, and reduced quality of life.
A more dangerous extrarenal manifestation is intracranial aneurysm. People with ADPKD have a higher risk of developing these weak-walled ballooning spots in brain arteries compared to the general population. One screening study of 355 ADPKD patients found aneurysms in about 12% of them, with the prevalence rising with age and peaking at roughly 23% in the 60-to-69 age group.13PubMed. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease Having a family history of aneurysm rupture or hemorrhagic stroke approximately doubled the risk.14Mayo Clinic Proceedings. Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Practical Approach to Screening and Management Current guidance generally recommends screening for brain aneurysms in ADPKD patients who have a family history of them, though practices vary by center.
The Economic Burden
About half of people with ADPKD progress to kidney failure by age 70, and ADPKD accounts for roughly 5% to 10% of all patients who need dialysis or a kidney transplant.15PubMed Central. End-Stage Kidney Disease in Patients With Autosomal Dominant Polycystic Kidney Disease: A 12-Year Study Based on the Canadian Organ Replacement Registry That downstream burden is enormously expensive. One estimate put the total economic cost of ADPKD in the United States at $7.3 billion in 2018, covering roughly 140,600 individuals. That works out to about $52,000 per person per year, with direct healthcare costs accounting for nearly 80% and the rest split between lost wages from unemployment and reduced productivity at work.16PubMed Central. The societal economic burden of autosomal dominant polycystic kidney disease in the United States
What drives those costs is not the early stages of the disease but the later ones. Healthcare spending stays relatively flat while kidney function is above a certain threshold, then jumps dramatically as it drops below. One analysis found that predicted four-year healthcare costs leaped from about $43,000 at moderate kidney disease to roughly $148,000 at the next stage, a roughly 3.5-fold increase, driven primarily by progression toward dialysis.17PubMed Central. Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease Another study confirmed that costs rose about fivefold when kidney filtration rates fell to very low levels compared to normal function.18PubMed Central. Renal function and healthcare costs in patients with polycystic kidney disease This steep cost curve is one of the strongest economic arguments for interventions that slow the decline, even modestly.
How Tolvaptan Is Changing the Treatment Landscape
For decades, ADPKD had no disease-specific treatment. Blood-pressure control and general kidney-health measures were the only tools available. That changed with the approval of tolvaptan, a drug that blocks a hormone receptor involved in cyst growth. Tolvaptan remains the only pharmacological agent proven to slow ADPKD progression, and it does so by reducing the rate at which kidney volume increases and slowing the decline in kidney function.19Frontiers in Medicine. Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study
A pooled analysis of clinical trials and observational studies in older ADPKD patients found that tolvaptan reduced the annual rate of kidney-function decline by about 1.7 mL/min/1.73 m² compared to standard care over three years.20Kidney Medicine. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies That sounds modest in absolute terms, but over years and decades it can translate into a meaningful delay in reaching kidney failure. The drug has significant side effects, including extreme thirst and the need to urinate frequently, and it requires regular liver-function monitoring, which limits adherence for some patients. Still, tolvaptan’s availability has shifted the conversation from passive monitoring to active management for those with rapidly progressing disease.
From a prevalence standpoint, tolvaptan’s impact is indirect. If the drug succeeds in delaying kidney failure by several years for a significant number of patients, it would increase the number of people living with ADPKD at any given time, since fewer would progress to transplant or death as early. In epidemiological terms, a disease that people live with longer produces a higher point prevalence even if the incidence of new cases hasn’t changed. This is worth keeping in mind as future prevalence studies are compared against older data.
Advances in Genetic Diagnosis
One reason the true prevalence of ADPKD has been hard to pin down is that genetic testing for the condition has historically been difficult. The PKD1 gene is large and sits in a region of chromosome 16 that has several near-identical copies, called pseudogenes, that confuse standard sequencing methods. A systematic review of molecular diagnostic approaches found that detection rates varied from about 61% with some older methods to 92% with targeted next-generation sequencing panels.21Global Medical Genetics. Molecular genetic diagnosis of autosomal dominant polycystic kidney disease – A systematic review
Newer techniques are closing the gap. Optimized exome sequencing has been shown to catch over 95% of defined PKD1 pathogenic variants, and higher-depth approaches have reached 100% detection in some studies.22Genetics in Medicine. Optimizing next-generation sequencing for genetic diagnosis in autosomal dominant polycystic kidney disease Long-read sequencing, a technology that reads much longer stretches of DNA in a single pass, has proved especially useful for cases that standard methods miss. In one study of 40 previously undiagnosed patients, the long-read approach more than doubled the genetic diagnosis rate compared to the standard short-read workflow, going from 20% to 45%.23npj Genomic Medicine. Targeted long-read sequencing enables higher diagnostic yield of ADPKD by accurate PKD1 genetic analysis
Better genetic testing doesn’t just help individual patients get a diagnosis. It also feeds back into prevalence research. As sequencing costs drop and accuracy improves, population-level screening studies become feasible, and the gap between “diagnosed prevalence” and “genetic prevalence” will narrow. The numbers we have now almost certainly undercount the disease, and the next generation of prevalence estimates, built on better genomic tools and larger electronic health record databases, will likely push the figure upward.
Why PKD Genes Are So Conserved Across Species
One of the curious things about the genes behind ADPKD is how old and how stable they are. The PKD2 gene family has been found across a wide range of mammalian species, and analyses of its evolutionary history show it has been under strong purifying selection, meaning mutations that break it get weeded out because the protein it encodes is essential for basic biological processes.24PubMed. Molecular evolution of PKD2 gene family in mammals The proteins made by PKD1 and PKD2 form part of a sensory structure on cells that helps them respond to fluid flow and mechanical stress, a function that matters in kidneys, liver, blood vessels, and other tissues.
PKD1 has a more complicated evolutionary story. In humans and African great apes, portions of the PKD1 gene have been duplicated into pseudogenes on the same chromosome. These extra copies don’t make functional protein, but they create the sequencing headaches described above and can also serve as templates for gene-conversion events that introduce new mutations.25PubMed Central. Chromosomal evolution of the PKD1 gene family in primates Orangutans and more distantly related primates lack these pseudogenes, which means the duplication events that make PKD1 so tricky to sequence are relatively recent in evolutionary terms. The paradox of ADPKD is that it involves ancient, critical genes whose function is tightly conserved across millions of years of evolution, yet the very chromosomal neighborhood in which PKD1 sits has made it unusually vulnerable to the kinds of mutations that cause disease in humans.